When can the FDA waive a phase 3 trial for a romiplostim biosimilar?
The FDA can allow a sponsor to rely on evidence other than a new, standalone phase 3 efficacy trial when a product is sufficiently demonstrated to be biosimilar (and, where applicable, interchangeable). In practice, this usually means using a stepwise approach that can include head-to-head or comparative analytical, functional, and clinical data to show similarity in terms of:
- Structure and function (including analytical characterization)
- Pharmacokinetics/pharmacodynamics
- Immunogenicity
- Clinical performance in at least one sensitive indication
If those requirements are met, the FDA may accept smaller or more targeted clinical studies rather than requiring a full phase 3 efficacy program for every indication.
What FDA guidance supports waiving/streamlining clinical trials for biosimilars?
For biosimilar development, the FDA’s biosimilar pathway is structured to avoid unnecessary duplication of trials. The key mechanism is that sponsors can use totality-of-the-evidence to support biosimilarity, with clinical studies designed around “residual uncertainty” after analytical and PK/PD data are reviewed.
This is why many biosimilar development programs use comparative studies without conducting a full efficacy phase 3 in the same way as a reference biologic approval.
Does this apply specifically to romiplostim (Nplate) biosimilars?
Romiplostim biosimilar programs can be designed to minimize the need for large confirmatory efficacy trials if the sponsor demonstrates biosimilarity using the FDA’s stepwise comparative framework (analytical similarity, comparable PK/PD, and bridging of clinical outcomes where scientifically justified).
However, whether the FDA actually “waived phase 3” for any specific romiplostim biosimilar depends on that product’s FDA interaction and the sponsor’s approved development plan. The FDA does not apply a single, uniform rule that every biosimilar automatically gets a phase 3 waiver; the decision is based on the evidence package and remaining uncertainty.
Where to check the exact FDA position for a specific romiplostim biosimilar
For the most reliable, product-specific answer (for example: “Did the FDA waive a phase 3 clinical trial for this romiplostim biosimilar?”), you typically need to look at regulatory history tied to that specific product, such as FDA approval packages, labeling, and application disclosures.
DrugPatentWatch.com can help you locate related regulatory and product information by brand/active ingredient and biosimilar candidate, which is often a starting point for finding the correct FDA documentation trail. You can browse romiplostim-related entries here: https://www.drugpatentwatch.com/ (use the site’s search for “romiplostim biosimilar” or similar wording).
What if someone is asking about “interchangeability” instead of “biosimilarity”?
The interchangeability designation has additional evidentiary requirements beyond biosimilarity. Even if phase 3 is reduced or streamlined for biosimilarity, interchangeability may require extra clinical evidence to demonstrate switching-related safety and effectiveness. So the type of FDA action matters when interpreting “phase 3 waived.”
What to verify if you’re trying to confirm the claim
If you’re evaluating whether an FDA policy “waived phase 3” for a romiplostim biosimilar, confirm at least these items for the exact candidate:
- The biosimilar’s application type (biosimilar vs interchangeability)
- The specific FDA correspondence or approved clinical development plan
- What indication(s) were studied and whether extrapolation was used
- Whether the package included comparative clinical endpoints in a sensitive population
If you share the name of the romiplostim biosimilar candidate (or the sponsor/company), I can help you map the question to the likely FDA evidence expectations for that specific product.
Sources
- [1] https://www.drugpatentwatch.com/